Get the Stockscreener App
15.27
0.86%
0.13
Forte Biosciences Inc stock is traded at $15.27, with a volume of 76,045.
It is up +0.86% in the last 24 hours and up +40.22% over the past month.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
See More
Previous Close:
$15.14
Open:
$15.15
24h Volume:
76,045
Relative Volume:
1.01
Market Cap:
$189.85M
Revenue:
-
Net Income/Loss:
$-31.48M
P/E Ratio:
-14.68
EPS:
-1.04
Net Cash Flow:
$-28.71M
1W Performance:
-1.42%
1M Performance:
+40.22%
6M Performance:
+159.25%
1Y Performance:
+217.46%
1-Day Range:
$14.50
$15.27
1-Week Range:
$13.76
$15.30
52-Week Range:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
15.27 | 188.23M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-25 | Initiated | Guggenheim | Buy |
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Why Forte Biosciences Inc. stock is a value investor pick2025 Price Momentum & Scalable Portfolio Growth Ideas - newser.com
Forecasting Forte Biosciences Inc. price range with options data2025 Support & Resistance & Safe Entry Zone Tips - newser.com
What institutional flow reveals about Forte Biosciences Inc.GDP Growth & Daily Entry Point Trade Alerts - newser.com
Is Forte Biosciences Inc. stock entering bullish territoryPortfolio Profit Report & Fast Gain Swing Alerts - newser.com
How to read the order book for Forte Biosciences Inc.Trade Risk Summary & Community Shared Stock Ideas - newser.com
Forte Biosciences Inc. stock prediction for this weekGap Down & Comprehensive Market Scan Reports - newser.com
Chart based analysis of Forte Biosciences Inc. trendsOil Prices & AI Driven Price Forecasts - newser.com
What makes Forte Biosciences Inc. (37T) stock appealing to growth investors2025 Market Trends & Real-Time Buy Zone Alerts - newser.com
Is Forte Biosciences Inc. building a consolidation baseInsider Selling & Daily Chart Pattern Signal Reports - newser.com
Forte Biosciences (NASDAQ:FBRX) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Forte Biosciences Inc. Reports Inducement Grants Under Nasdaq Listing Rules - MarketScreener
Can a trend reversal in Forte Biosciences Inc. lead to recoveryTrend Reversal & Weekly High Conviction Ideas - newser.com
Will Forte Biosciences Inc. continue its uptrendDollar Strength & Fast Moving Stock Trade Plans - newser.com
Forte Biosciences reports inducement grants under Nasdaq listing rules - MarketScreener
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - MarketScreener
Will Forte Biosciences Inc. (37T) stock outperform Dow JonesTrade Performance Summary & Free Low Drawdown Momentum Trade Ideas - newser.com
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - MarketBeat
How to build a dashboard for Forte Biosciences Inc. stock2025 Technical Overview & Accurate Entry and Exit Point Alerts - newser.com
Forte Biosciences (FBRX) Price Target Increased by 16.98% to 53.30 - Nasdaq
What to do if you’re stuck in Forte Biosciences Inc.2025 Institutional Moves & Long Hold Capital Preservation Plans - newser.com
Can ACE Edutrend Limited Maintain Its Growth Rate as a Small CapPrice Volatility Patterns & 100% Free Stock Analysis for Smarter Decisions - earlytimes.in
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Forte Biosciences Inc Stock (FBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wagner Paul A. | SEE REMARKS |
Oct 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
82,190 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jul 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,733 |
| Wagner Paul A. | SEE REMARKS |
Jul 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
81,038 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Apr 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,372 |
| Wagner Paul A. | SEE REMARKS |
Apr 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
79,806 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,151 |
| Wagner Paul A. | SEE REMARKS |
Jan 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
78,720 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Nov 21 '24 |
Buy |
5.55 |
22,514 |
124,998 |
30,776 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):